What Your Tumor Biology Data Isn’t Telling You: Closing the Functional Gap with Proteomics

We show how these workflows simultaneously resolve surface target accessibility for ADC, T-cell engager, and radioligand therapy programs, as well as phosphorylation-driven pathway activation, immune cell composition, and resistance-associated protein networks: the functional dimensions of tumor biology that determine whether a drug will be effective in the patient tumor. You’ll come away with:

• An understanding of how mass spectrometry-based proteomics delivers functional tumor biology data from FFPE and fresh-frozen tissue at scale
• Appreciation for where protein-level evidence can augment or replace genomic inference at critical decision points in oncology drug development, from target selection through translational biomarker strategy
• Real-world examples of mass spectrometry-based proteomics applied across diverse tumor samples to reveal novel insights into cell surface targets, functional tumor signaling, immune activation, and resistance mechanisms with single protein and pathway-level resolution

Data from ovarian, colorectal, lung, and other tumor types will illustrate the novel insights uncovered through protein-level profiling that are missed by sequencing alone. You’ll gain a practical understanding of how functional proteomics evidence can be incorporated earlier in development programs – and what that means for target selection, biomarker strategy, and clinical readiness.

Complete the form to access the full recording!